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Magnesium has been used empirically for several decades 
in the treatment of atrial and ventricular arrhythmias 
in patients with normal and decreased serum magnesium 
levels. However, a systematic evaluation of the effects 
of magnesium on cardiac conduction and refractoriness 
in humans has not been described. In this study, the 
electrocardiographic and electrophysiologic effects of 
magnesium were determined in 10 patients with normal 
baseline serum magne~ium and other electrolyte levels. 
Six grams of magnesium sulfate was administered in-
travenously over 6 minutes followed by a continuous 
infusion of 1 additional gram over 1 hour. Serum mag-
nesium levels rose significantly from a baseline of 2.0 ± 
0.2 to 5.4 ± 0.4 mg/dl (p < 0.001). 
No significant change occurred in heart rate at rest, 
or in duration of the QRS complex or QT or QTc in-
tervals during sinus rhythm. There were significant in-
creases in sinus node recovery time (1,000 ± 211 to 1,106 
± 223 ms, p < 0.01) and corrected sinus node recovery 
The sulfate and chloride salts of magnesium have been used 
intravenously for several decades in the short-term treatment 
of patients with atrial and ventricular arrhythmias (1-6). In 
these uncontrolled studies, variable doses of magnesium 
were administered over several seconds or minutes to ter-
minate paroxysmal atrial tachycardia (l ,2), to decrease the 
ventricular rate during atrial fibrillation (2.3) and to suppress 
ventricular extrasystoles associated with digitalis intoxica-
tion (2,3). Magnesium has also been used empirically, often 
in conjunction with other antiarrhythmic drugs or interven-
tions, in the treatment of intractable ventricular tachycardia. 
ventricular fibrillation and torsade de pointes in patients with 
normal and decreased serum magnesium levels (4-7). The 
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time (279 ± 87 to 336 ± 104 ms, p < 0.05). Significant 
increases occurred in atrioventricular (A V) node con-
duction time during sinus rhythm (82 ± 22 to 97 ± 17 
ms, p < 0.02), in the atrial paced cycle length at which 
A V node Wenckebach block occurred (350 ± 46 to 419 
± 65 ms, p < 0.01) and in the AV node relative re-
fractory period (397 ± 27 to 422 ± 18 ms, p < 0.05), 
functional refractory period (395 ± 41 to 415 ± 33 ms, 
p < 0.05) and effective refractory period (306 ± 67 to 
338 ± 38 ms, p < 0.05). During rapid ventricular pacing 
at 500 and 250 ms, QRS duration increased significantly 
(154 ± 15 to 164 ± 20 ms, p < 0.01) but was not rate 
dependent. There was no significant change in atrial or 
ventricular refractory periods. 
Acute intravenous administration of magnesium has 
several electrophysiologic effects that may be beneficial 
in the treatment of atrial and ventricular arrhythmias. 
(J Am Coil CardioI1986;7:1356-62) 
antiarrhythmic effects of magnesium have been reported to 
last from several minutes to as long as 24 hours (2); how-
ever, the serum half-life of intravenously administered mag-
nesium is very short. It is excreted by the kidney almost 
entirely within 4 to 8 hours in patients with normal renal 
function (8). 
Although the electrocardiographic and electrophysiologic 
effects of intravenous magnesium administration have been 
described in experimental animals, a systematic evaluation 
of the effects of magnesium in humans has not been re-
ported. The purpose of this study, therefore, was to deter-
mine the effects of intravenously administered magnesium 
sulfate on cardiac conduction and refractoriness in humans. 
Methods 
Patients studied. Approval for administration of intra-
venous magnesium sulfate was obtained from the Institu-
tional Review Board at our medical center. Subjects for this 
study were recruited from patients undergoing a routine 
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electrophysiologic evaluation for clinical indications, Be-
cause our study was intended to examine only the effects 
of magnesium on cardiac conduction and refractoriness, we 
excluded patients in whom sustained atrial or ventricular 
tachycardia was initiated during their clinical electrophys-
iologic evaluation, 
There were seven men and three women in this study 
with a mean age of 54 ± 12 years, Three patients had 
ischemic cardiomyopathy, two had idiopathic dilated car-
diomyopathy, one had alcoholic cardiomyopathy and four 
had no clinical evidence of heart disease, One patient had 
left bundle branch block, one had a nonspecific intraven-
tricular conduction delay that exceeded 120 ms, five had a 
nonspecific intraventricular conduction delay of less than 
120 ms, and three had normal intraventricular conduction 
on a 12 lead electrocardiogram at rest before administration 
of magnesium, Clinical indications for electrophysiologic 
study were evaluation of ventricular tachycardia (four pa-
tients) and syncope (six patients), All patients had normal 
serum sodium, potassium chloride, bicarbonate, calcium 
and magnesium levels at the time of study, 
Protocol of electro physiologic study. All antiar-
rhythmic drugs were withheld for at least five half-lives 
before study, Electrophysiologic studies were performed 
with patients in the fasting non sedated state after written, 
informed consent was obtained, Two or three 6F quadripolar 
electrode catheters (USCI) with a I cm interelectrode dis-
tance were introduced percutaneously into the right femoral 
vein and positioned under fluoroscopic guidance in the high 
right atrium, across the tricuspid valve in the region of the 
His bundle and in the right ventricular apex, Systemic blood 
pressure was monitored continuously with a SF indwelling 
cannula introduced percutaneously into the right femoral 
artery and connected to a Statham P23-ID pressure trans-
ducer (Gould Medical Products), Intracardiac electrograms 
were filtered below 30 and above 500 Hz and were displayed 
simultaneously with scalar electrocardiographic leads V I, I 
and III on a multichannel oscilloscope (Electronics-for-
Medicine, VR-16), Signals were recorded on photographic 
paper at speeds of 50 to 150 mm/s, Programmed cardiac 
stimulation was performed with a programmable constant 
current stimulator (Bloom Associates) that delivered rec-
tangular pulses of 2 ms duration at twice diastolic threshold, 
After measuring the heart rate at rest and scalar electro-
cardiographic P wave, PR, QRS and QT intervals and base-
line atrial-His (AH), His-ventricular (HV) and P wave-(high 
right) atrial (PA) intervals, atrial overdrive pacing was per-
formed for durations of 1 minute at cycle lengths of 600 
ms down to 300 ms in 50 ms decrements, This was done 
to determine uncorrected and corrected sinus node recovery 
times, AH and HV intervals and the paced cycle length at 
which atrioventricular (A V) Wenckebach block occurred, 
Atrial and ventricular effective refractory periods were de-
termined in duplicate at atrial and ventricular drive cycle 
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lengths of 500 ms using a drive train of 8 paced cycles with 
a 3 second intertrain pause, Right ventricular pacing was 
then performed for at least 15 beats at cycle lengths of 500 
and 250 ms, The last five QRS complexes of each pacing 
train were recorded at a paper speed of 150 mm/s. 
Magnesium administration. Immediately after com-
pletion of the protocol, 6 g of 4% magnesium sulfate so-
lution was intravenously administered at a rate of I g/min. * 
Because of the short half-life of intravenous magnesium, a 
continuous infusion of 4% magnesium sulfate solution was 
then initiated at a rate of 1 g/hour. t Ten minutes later, the 
entire pacing protocol was repeated. Serum magnesium lev-
els were obtained immediately before intravenous admin-
istration of magnesium sulfate and immediately after the 
pacing protocol was repeated. Serum magnesium content 
was determined using the methylthymol blue complex col-
orimetric procedure (DuPont aca III analyzer) (9). 
Data analysis. Uncorrected and corrected sinus node 
recovery times, AH and HV intervals and atrial and ven-
tricular effective refractory periods were determined using 
standard methods and previously described definitions (10). 
The scalar electrocardiographic QT interval was corrected 
(QTc) using Bazett's formula (11). Using a previously de-
scribed method (12), the duration of the last QRS complex 
recorded during ventricular pacing at cycle lengths of 500 
and 250 ms was measured as an index of intraventricular 
conduction from electrocardiographic lead III which, in all 
cases, provided the best definition of the onset and termi-
nation of the QRS complex. The duration of this QRS com-
plex train was measured in blinded fashion by two inves-
tigators. Reproducibility was within 5%. 
Because of practical considerations, data acquisition was 
limited in 4 of the 10 cases. In one patient, who demon-
strated accelerated A V node conduction during the baseline 
study, QRS, QT and QTc intervals recorded during sinus 
rhythm, all AH and HV intervals and the paced cycle length 
causing A V node Wenckebach conduction were excluded. 
In two patients, who demonstrated Wenckebach block at a 
paced cycle length of at least 500 ms after magnesium was 
administered, and in the fourth patient, in whom a stable 
His bundle depolarization could not be consistently re-
corded, A V node effective, functional and relative refrac-
tory periods could not be determined. 
Statistical analysis was performed using the paired t test. 
All values are expressed as mean ± SD. 
Results 
Patients uniformly experienced a sensation of increased 
warmth with flushing and diaphoresis associated with cu-
*This dose was chosen to represent a mIdrange dose when compared 
with the administered doses reported In prevIOus ,(udies (1-7.13.16). 
tThis dose was given because of short excretion time of magnesium 
and because of previous use of continuous intravenous infUSIOn (4.5,7). 
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Figure 1. Serum magnesium concentrations before and after 
administration of magnesium sulfate in 10 patients. 
taneous vasodilation and a transient decrease in blood pres-
sure during short-term loading with magnesium sulfate. No 
depression of respiratory rate occurred in any patient. All 
symptoms and signs resolved spontaneously and heart rate 
and blood pressure returned to baseline within 2 to 3 minutes 
after loading was completed, and did not recur during con-
tinued infusion of 1 g magnesium sulfate over the next hour. 
Serum magnesium levels rose significantly (from 2.0 ± 
0.2 to 5.4 ± 0.4 mg/dl, p < 0.001) after intravenous admin-
istration of magnesium sulfate (Fig. 1). 
Electrocardiographic effects (Table 1). Magnesium 
caused a significant increase in the electrocardiographic PR 
interval (167 ± 19 to 187 ± 18 ms, p < 0.001) (Fig. 2). 
No significant change occurred in heart rate (81 ± 19 versus 
78 ± 14 beats/min, p = NS), P wave duration (106 ± 27 
versus 113 ± 39 ms, p = NS), QRS duration (113 ± 27 
versus 117 ± 31 ms, p = NS), QT interval (383 ± 35 
versus 388 ± 30 ms, p = NS) or corrected QT interval 
(QTc) (443 ± 37 versus 451 ± 42 ms, p = NS). Com-
parison of 12 lead electrocardiograms before and after mag-
nesium administration demonstrated no changes in P wave, 
QRS complex, ST segment or T wave configuration. 
Electrophysiologic effects (Table 2). Sinus node func-
tion. No significant change in spontaneous sinus cycle length 
occurred after administration of magnesium (737 ± 178 to 
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768 ± 139 ms, p = NS). However, significant increases 
were noted in the longest sinus node recovery time 
(1,000 ± 211 to 1,106 ± 223 ms, p < 0.01) and the 
longest corrected sinus node recovery time (279 ± 87 to 
336 ± 104 ms, p < 0.05) measured after administration 
of magnesium (Fig. 3). 
Atrioventricular conduction. Magnesium caused a sig-
nificant increase in the AH interval (82 ± 22 to 97 ± 17 
ms, p < 0.02) during sinus rhythm without a significant 
change in scalar electrocardiographic P wave duration 
(106 ± 27 to 113 ± 39 ms, p = NS), intracardiac atrial 
electrogram duration (60 ± 12 to 64 ± 10 ms, p = NS) 
or P-A interval (16 ± 12 to 17 ± 11 ms, p = NS). The 
atrial paced cycle length at which A V node Wenckebach 
block occurred was significantly prolonged after adminis-
tration of magnesium (350 ± 46 to 419 ± 65 ms, p < 
0.01) (Fig. 2). Magnesium caused no significant change in 
HV interval during sinus rhythm (47 ± 4 to 47 ± 5 ms, 
p = NS) or during atrial overdrive pacing. 
Atrioventricular node refractoriness. After administra-
tion of magnesium sulfate, significant increases occurred 
in the A V node functional refractory period (395 ± 41 
to 415 ± 33 ms, p < 0.05), relative refractory period 
(397 ± 27 to 422 ± 18 ms, p < 0.05) and effective 
refractory period (306 ± 67 to 338 ± 38 ms, p < 0.05) 
(Fig. 4). 
Intraventricular conduction. The duration of intraven-
tricular conduction was similar during rapid ventricular pac-
ing at cycle lengths of 500 and 250 ms before administration 
of magnesium (154 ± 15 versus 154 ± 15 ms, p = NS). 
After administration of magnesium, it increased signifi-
cantly during ventricular pacing at cycle lengths of 500 ms 
(154 ± 15 to 164 ± 20 ms, p < 0.01) and 250 ms 
(154 ± 15 to 164 ± 18 ms, p < 0.01) (Fig. 5). 
Atrial refractoriness. Magnesium caused no significant 
change in the atrial functional refractory period (253 ± 20 
to 261 ± 21 ms, p = NS), relative refractory period 
(246 ± 27 to 285 ± 80 ms, p = NS) or effective refractory 
period (213 ± 18 to 235 ± 33 ms, p = NS). 
Ventricular refractoriness. Magnesium caused no sig-
nificant change in ventricular effective refractory period 
(233 ± 20 to 235 ± 15 ms, p = NS). 
Table 1. Electrocardiographic Effects of Magnesium Sulfate* 
Baseline Magnesium p Value 
Heart rate (beats/min) (n = 10) 81 ± 19 78 ± 14 NS 
P wave duration (ms) (n = 10) 106 ± 27 113 ± 39 NS 
Interval 
PR (ms) (n = 9) 167 ± 19 187 ± 18 < 0.01 
QRS (ms) (n = 9) 113 ± 27 117 ± 31 NS 
QT (ms) (n = 9) 383 ± 35 388 ± 30 NS 
QTc (ms) (n = 9) 443 ± 37 451 ± 42 NS 
* All data recorded on scalar electrocardiogram during sinus rhythm. n = number of patients; NS = not 
significant; QTc = QT interval corrected for heart rate (Bazetl's formula). 
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Figure 2. PR and atrial-His (AH) intervals. and the longest paced 
atrial cycle length causing AV node Wenckebach block (AVN 
WCL) before and after administration of magnesium sulfate m 
nine patients. 
of variability in the quantity of magnesium administered, 
the varying duration of intravenous administration and the 
absence of serum magnesium determinations before and 
after treatment in earlier studies. No significant change in 
heart rate or duration of QRS complex or QT interval oc-
curred in this study after administration of 6 g magnesium 
sulfate over 6 minutes. Previous authors (6,13) noted no 
change in heart rate or QT interval after administration of 
I to 2 g magnesium sulfate over 10 seconds to 1 to 2 minutes. 
After giving 4 g magnesium sulfate over 4 to 10 seconds, 
Discussion 
Electrocardiographic effects. The electrocardiographic 
effects of magnesium sulfate demonstrated in this study are 
in general agreement with those described by previous au-
thors. A strict comparison is not possible, however. because 
Table 2. Electrophysiologlc Effects of Magnesium Sulfate 
Baseline 
Sinus node function 
SSCL (n = 10) 737 :±: 178 
SNRT (n = 10) 1.000 :±: 211 
SNRTc (n = 10) 279 :±: 87 
Atnoventncular conduction 
A (n = 10) 60 :±: 12 
AH (n = 8) 82 :±: 22 
AVN WBB (n = 9) 350 :±: 46 
HV (n = 8) 47 :±: 4 
P-A (n = 10) 16 :±: 12 
A V node refractoriness 
AVNERP (n = 6) 306 :±: 67 
A VNFRP (n = 6) 395 ± 41 
A VNRRP (n = 6) 397 :±: 27 
Intraventncular conduction 
QRSsoo (n = 10) 154 :±: 15 
QRS250 (n = 10) 154 :±: 15 
Atrial refractoriness 
AERP (n = 7) 213 :±: 18 
AFRP (n = 7) 253 :±: 20 
ARRP (n = 7) 246 :±: 27 
Ventricular refractoriness 
VERP (n = 10) 233 ± 20 
Magnesium p Value 
768 :±: 139 NS 
1.106 :±: 223 < 0.01 
336 :±: 104 < 005 
64 :±: 10 NS 
97 :±: 17 < 002 
419 :±: 65 < 0.01 
47 :±: 5 NS 
17 :±: II NS 
338 :±: 38 < 0.05 
415 :±: 33 < 005 
422 ± 18 < 0.05 
164 ± 20 < 0.01 
164 ± 18 < 0.01 
235 ± 33 NS 
261 ± 21 NS 
285 :±: 80 NS 
235 ± 15 NS 
All values in ms. A atrial septal electrogram duration, AERP = atrial effective refractory period; 
AFRP = atnal functIOnal refractory period; AH = atnal-His interval; ARRP = atrial relative refractory period; 
A VN = atrioventricular node; A VNERP, A VNFRP and A VNRRP = atrioventncular node effective, functIOnal 
and relative refractory period, respectively; A VN WBB = atrial paced cycle length causing atrioventricular 
node Wenckebach conduction; HV = His-ventricular mterval; n = number of patients; P = scalar electro-
cardiographic P wave duration; P-A == scalar electrocardiographic P wave-mtracardiac (high right) atrial 
electrogram mterval; QRS2S0 and QRSsoo = QRS duration during ventricular pacing at a cycle length of 250 
and 500 ms, respectively; SNRT = sinus node recovery time; SNRTc = corrected SNRT; SSCL = spontaneous 
sinus cycle length; VERP = right ventricular apex effective refractory penod. 
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Figure 3. The longest measured sinus node recovery time (SNRT) 
and the longest measured corrected sinus node recovery time (SNRTc) 
before and after administration of magnesium sulfate in nine pa-
tients. 
Enselberg et al. (3) reported an initial increase followed by 
slowing of the heart rate, whereas Szekely (2) found minor 
alterations in heart rate in only 4 of lO patients given a 
similar dose over 2 minutes. During administration of lO g 
of magnesium sulfate over 30 to 60 minutes with continuous 
electrocardiographic monitoring, Winkler et al. (14) ob-
served no significant slowing of heart rate. 
Sinus node effects. Although no significant change in 
heart rate at rest occurred after administration of magnesium 
sulfate in this study, sinus node recovery time and corrected 
sinus node recovery time were significantly prolonged. Sev-
eral studies in animals suggest that this may be mediated 
by both indirect and direct inhibitory effects of magnesium 
on the sinoatrial node. Magnesium has been demonstrated 
(15) to slow the heart rate at rest by inducing a short-lived 
blockade of the nictating membrane of the sympathetic gan-
glia and by preventing the stimulating effects of potassium 
and acetylcholine on the superior cervical ganglion of anes-
thetized cats. Magnesium does not release the heart from 
vagal inhibition; conversely, it continues to have a negative 
chronotropic effect after administration of atropine or sec-
tioning of the vagus nerve (16). It continues to slow the 
heart rate at rest in a dose-dependent fashion even after the 
heart has been decentralized by crushing of the cervical 
sympathicovagal trunks (IS). 
450 
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Atrioventricular node effects. Magnesium induced a 
prolongation of A V node conduction time during sinus rhythm 
and an increase in the paced cycle length at which A V node 
Wenckebach block occurred. These findings are compatible 
with previous observations of prolongation of the PR and 
A V intervals during sinus rhythm and a decrease in ven-
tricular rate during atrial fibrillation after administration of 
intravenous magnesium (1-3,5,17). Significant increases in 
A V node functional, relative and effective refractory periods 
caused by magnesium were also observed in our study. In 
vitro studies (18) have demonstrated an increase in A V node 
conduction time and a decrease in the spontaneous firing 
frequency of the A V node in isolated rabbit hearts exposed 
to a 5 mM concentration of magnesium cation as compared 
with the mean serum concentration of 2.2 mM achieved 
after administration of magnesium in this study. Although 
magnesium has been proposed by some authors (19) as 
nature's calcium antagonist, it appears to exert its negative 
dromotropic and chronotropic effects on the A V node in-
directly. Magnesium induces an inward shift of the back-
ground potassium-mediated current, causing a secondary 
voltage-dependent inactivation of the slow inward current 
which mediates AV node depolarization (18). Magnesium 
exhibits a different mode of action, therefore, than the direct 
inactivation of the slow inward current observed with other 
calcium channel antagonists, such as verapamil (20). 
Myocardial effects. Magnesium had no significant ef-
fect on His-Purkinje conduction time or QRS duration at 
heart rates at rest. These findings are consistent with those 
of previous studies (2,5) that reported no increase in QRS 
duration or development of intraventricular block in humans 
given intravenous magnesium. An increase in QRS duration 
was reported in dogs (16,21), but only when they were given 
lethal doses of magnesium. In our study, magnesium was 
demonstrated to have a small but statistically significant 
effect on intraventricular conduction during rapid ventricular 
Figure 4. Atrioventricular node (A VN) functional refractory pe-
riod (FRP), relative refractory period (RRP) and effective refrac-
tory period (ERP) before and after administration of magnesium 
sulfate in six patients. 
450 400 
I I~I AVN I AVN RRP ERP 'msi 400 mSI 300 
/<""' 350 peOOS 200 '( of I I I i 
Control MagneSium Control MagneSium 
JACC Vol. 7, No.6 



















pacing. Individual increases ranged from 0 to 18% with a 
mean increase of 6% for the patient group, The observed 
increases were similar at paced cycle lengths of 500 and 
250 ms, suggesting that the effect of magnesium on ven-
tricular conduction is tonic and unlike the rate-dependent 
increase in intraventricular conduction observed with type 
1 and type 3 antiarrhythmic drugs (12). Although this tonic 
effect on intraventricular conduction could not be demon-
strated during sinus rhythm, such an effect cannot be ex-
cluded with certainty, The scalar electrocardiographic QRS 
complex recorded during sinus rhythm was much narrower 
than the broad QRS complex recorded during ventricular 
pacing; this may have made a subsequently small but sig-
nificant increase in intraventricular conduction much more 
difficult to detect. Alternatively, the lack of effect of mag-
nesium on QRS duration during sinus rhythm may reflect 
an absence of effect on the His-Purkinje system, which 
initiates ventricular depolarization, whereas an increase in 
QRS duration during ventricular pacing may reflect the ef-
fect of magnesium on the myocardial tissue which is ini-
tiating and propagating ventricular depolarization, 
Several lines of evidence suggest that the effects of mag-
nesium on myocardial muscle fibers do not occur as a result 
of interaction with the fast sodium-mediated channel or the 
slow calcium-mediated channel in the excited myocardial 
sarcolemma membrane. The effects of magnesium on action 
potential are not blocked by tetrodotoxin, lidocaine or cal-
cium antagonists such as verapamil, D600, nifedipine or 
diltiazem (22). Magnesium may instead have a direct effect 
on potassium channels in the sarcolemmic membrane (22-24). 
Watanabe and Dreifus (24) observed minimal changes in 
action potential amplitude, rest potential and maximal rate 
of depolarization of isolated ventricular muscle fibers ex-
posed to a 7.5 mM concentration of magnesium ion. A small 
but significant (4,3%) increase in action potential duration 
and a 10 to 30 ms prolongation of the ventricular effective 
refractory period were observed. Although magnesium sul-
fate appeared to have no significant effect on atrial or ven-
tricular refractoriness in their study, the mean serum con-
centration was much lower (2.2 mM). Furthermore, it is 
possible that other compensatory neurogenic mechanisms 
p<0.01 
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Figure 5. QRS duration during ventricular pacing at 
cycle lengths of 500 ms (QRS500) and 250 ms (QRS250) 
before and after administration of magnesium sulfate 
in 10 patients. 
Magnesium 
occur in vivo which may offset any direct effect of mag-
nesium on myocardial muscle repolarization. 
Antiarrhythmic effects of magnesium. Magnesium has 
been used empirically for more than 40 years (1-7) to treat 
atrial and ventricular arrhythmias in a variety of clinical 
settings including hypoxemia, myocardial ischemia and in-
farction, electrolyte depletion due to malnutrition or diuretic 
therapy and complications of treatment with digitalis gly-
cosides and type 1 or type 3 antiarrhythmic drugs, for ex-
ample, drug-induced torsade de pointes (6,7). However, the 
specific role of magnesium in the treatment of cardiac ar-
rhythmias has been unclear, In the clinical studies published 
to date, serum magnesium levels before treatment have often 
been unknown, or serum magnesium and other electrolyte 
levels have been normal, making it difficult to distinguish 
whether subsequently successful treatment with magnesium 
was due to repletion of a magnesium deficiency or to a 
separate antiarrhythmic effect. In many cases, the mecha-
nism of the treated arrhythmia has not been defined and 
other antiarrhythmic drugs or interventions have been used 
concurrently with intravenous magnesium, preventing a clear 
determination of the antiarrhythmic effects of magnesium 
alone, 
In this study, administration of intravenous magnesium 
to patients with normal serum electrolyte levels caused a 
significant decrease in sinus node and AV node functions, 
In some patients, therefore, magnesium might be useful in 
the treatment of arrhythmias whose mechanism depends on 
participation of the sinoatrial or A V node (such as supra-
ventricular arrhythmias due to sinoatrial reentry, A V node 
reentry or reciprocating tachycardia) or arrhythmias whose 
mechanism depends on slow channel activity (for example, 
ventricular arrhythmias due to digitalis toxicity or triggered 
automaticity) (3,25), 
When administered in a dose that met or exceeded many 
of the doses previously reported to be effective in the treat-
ment of ventricular arrhythmias, magnesium had no effect 
on ventricular refractoriness and caused a small but statis-
tically significant decrease in intraventricular conduction in 
the patients participating in this study, It is noteworthy, 
however, that the observed decrease in ventricular conduc-
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tion was minimal when compared with that reported (12) 
for other antiarrhythmic agents known to decrease the fast 
sodium-dependent channel activity that mediates ventricular 
muscle depolarization. These findings suggest that mag-
nesium might be unlikely to have a significant antiar-
rhythmic effect in the treatment of ventricular tachycardia 
due to a reentrant mechanism (26,27). 
Conclusions. Although intravenously administered 
magnesium has several significant electrophysiologic effects 
in humans, the relation of these electrophysiologic findings 
to the potential antiarrhythmic effects of magnesium is not 
clear. Despite several decades of use in treatment of cardiac 
arrhythmias, the clinical use of magnesium has been spo-
radic and infrequent and its antiarrhythmic effects have been 
poorly understood. Additional studies may be helpful in 
determining its antiarrhythmic efficacy. 
We are grateful to Beverly Burgie, Marsha Martin and Gail Connor for 
technical assistance in the cardiac electrophysiology laboratory, and to Lisa 
Hackbarth for preparation of this manuscnpt. 
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